Literature DB >> 20337302

Vitrectomy, Laser Photocoagulation, and Intravitreal Triamcinolone for Combined Hamartoma of the Retina and Retinal Pigment Epithelium.

Dong Heun Nam, Kwang Hoon Shin, Dae Yeong Lee, Hee Jin Sohn.   

Abstract

Combined hamartoma of the retina and retinal pigment epithelium (CHRRPE) is a rare, benign tumor, but there are no established managements for CHRRPE. A patient with CHRRPE who is treated successfully by the new combination therapy was described. A 32-year-old man was diagnosed as having CHRRPE after evaluation with ophthalmoscopy, fluorescein angiography (FA), and optical coherence tomography (OCT). First performed intravitreal triamcinolone acetonide (IVTA) (4 mg/0.1 mL) and laser photocoagulation to treat the vascular component. There was a rapid and good response after that therapy, but a recurrence 3 months later. To relieve the glial component, we simultaneously combined vitrectomy with IVTA and laser photocoagulation. After the combination therapy, there were no recurrences or complications. A combination therapy of vitrectomy, laser photocoagulation, and intravitreal triamcinolone could be considered as a possible management for CHRRPE with the vascular and glial components. Copyright 2010, SLACK Incorporated.

Entities:  

Year:  2010        PMID: 20337302     DOI: 10.3928/15428877-20100215-70

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  2 in total

1.  Combined hamartoma of the retina and retinal pigment epithelium.

Authors:  Kanmin Xue; Faye Mellington; Irina Gout; Sofia Rokerya; Oyinkan Ibironke Olurin; Ahmed El-Amir
Journal:  BMJ Case Rep       Date:  2012-11-15

Review 2.  [Retinal tumors in adults: Part 2 nonvascular tumors of retina and retinal pigment epithelium].

Authors:  Roya Piria; Felix Rommel; Michael Zimbelmann; Kristina Erikson; Neele Babst; Anton Brosig; Josephine Christin Freitag; Mahdy Ranjbar; Salvatore Grisanti; Vinodh Kakkassery
Journal:  Ophthalmologe       Date:  2021-07-29       Impact factor: 1.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.